CompletedPhase 2

Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

Switzerland50 participantsStarted 2016-03

Plain-language summary

Glucagon like Peptide -1 (GLP-1) receptor agonists are well known to stimulate glucose-induced insulin secretion and to reduce energy intake. Recent findings from animal and human studies suggest a role of GLP-1 in regulating water and salt homeostasis. GLP-1 has been shown to reduce fluid intake after an oral salt load or during a meal - pointing to a hypodipsic effect. The aim of this study is to elucidate whether these putative hypodipsic properties of GLP-1 might be of advantage in persons with an exaggerated thirst perception as is the case in patients with primary polydipsia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age over 18 years * Polyuria of \> 50 ml/Kg/day * Polydipsia of \> 3 liters/day Exclusion Criteria: * Known or probable central or nephrogenic Diabetes insipidus, expected from patient's history * Polyuria secondary to diabetes mellitus, hypokalemia, hypercalcemia * Pregnancy * Previous treatment with GLP-1 agonists within the last 3 month * History of pancreatitis * Severe renal insufficiency (eGFR (CKD EPI) \<30 ml/min/1,73 m2) * Cancer

What they're measuring

Fluid intake in ml

Timeframe: 8 hours

Trial details

NCT IDNCT02770885

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-05-17

View on ClinicalTrials.gov More Primary Polydipsia trials